MX2021012200A - Adyuvante soluble en agua y composición que contiene el mismo. - Google Patents

Adyuvante soluble en agua y composición que contiene el mismo.

Info

Publication number
MX2021012200A
MX2021012200A MX2021012200A MX2021012200A MX2021012200A MX 2021012200 A MX2021012200 A MX 2021012200A MX 2021012200 A MX2021012200 A MX 2021012200A MX 2021012200 A MX2021012200 A MX 2021012200A MX 2021012200 A MX2021012200 A MX 2021012200A
Authority
MX
Mexico
Prior art keywords
composition containing
water soluble
containing same
soluble adjuvant
compound
Prior art date
Application number
MX2021012200A
Other languages
English (en)
Inventor
Yosuke Takanashi
Hitoshi Ban
Yusuke Imazaki
Original Assignee
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma Co Ltd filed Critical Sumitomo Pharma Co Ltd
Publication of MX2021012200A publication Critical patent/MX2021012200A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Abstract

La presente invención se refiere a un compuesto útil como adyuvante de vacuna para vacuna contra el cáncer, un procedimiento de preparación del mismo, una composición farmacéutica que comprende el compuesto y el uso del compuesto como adyuvante de vacuna para una vacuna contra el cáncer.
MX2021012200A 2019-04-05 2020-04-03 Adyuvante soluble en agua y composición que contiene el mismo. MX2021012200A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019072911 2019-04-05
PCT/JP2020/015364 WO2020204173A1 (ja) 2019-04-05 2020-04-03 水溶性アジュバントおよびそれを含有する組成物

Publications (1)

Publication Number Publication Date
MX2021012200A true MX2021012200A (es) 2022-01-06

Family

ID=72668989

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012200A MX2021012200A (es) 2019-04-05 2020-04-03 Adyuvante soluble en agua y composición que contiene el mismo.

Country Status (9)

Country Link
US (1) US20220241409A1 (es)
EP (1) EP3954382A4 (es)
JP (1) JPWO2020204173A1 (es)
KR (1) KR20220004030A (es)
CN (1) CN113905758A (es)
AU (1) AU2020255935A1 (es)
CA (1) CA3136066A1 (es)
MX (1) MX2021012200A (es)
WO (1) WO2020204173A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6718562B1 (ja) 2018-07-24 2020-07-08 日本化薬株式会社 エポキシ樹脂、エポキシ樹脂組成物、炭素繊維強化複合材料用エポキシ樹脂組成物、プリプレグ、炭素繊維強化複合材料
AU2022327884A1 (en) * 2021-08-12 2024-02-22 International Institute Of Cancer Immunology, Inc. Pharmaceutical composition and method for treatment or prevention of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8178102B2 (en) 2005-01-19 2012-05-15 Dainippon Sumitomo Pharma Co., Ltd. Emulsified composition for dilution and cancer vaccine composition
JP4394724B2 (ja) 2005-11-30 2010-01-06 株式会社癌免疫研究所 新規ペプチド化合物
SG173617A1 (en) * 2009-02-11 2011-09-29 Univ California Toll-like receptor modulators and treatment of diseases
MY171854A (en) 2013-03-29 2019-11-05 Sumitomo Dainippon Pharma Co Ltd Wt1 antigen peptide conjugate vaccine
WO2014157704A1 (ja) 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｅｒａｐ１によるトリミング機能をきっかけとしたコンジュゲートワクチン
ES2805724T3 (es) * 2015-09-29 2021-02-15 Sumitomo Dainippon Pharma Co Ltd Compuestos de adenina conjugados y su uso como adyuvantes de vacunas
MA48862A (fr) * 2017-05-02 2020-04-01 Nektar Therapeutics Méthode de traitement de tumeur immunothérapeutique
AU2019277094A1 (en) * 2018-05-29 2021-01-21 Bristol-Myers Squibb Company Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making

Also Published As

Publication number Publication date
KR20220004030A (ko) 2022-01-11
EP3954382A4 (en) 2022-12-21
US20220241409A1 (en) 2022-08-04
CN113905758A (zh) 2022-01-07
CA3136066A1 (en) 2020-10-08
WO2020204173A1 (ja) 2020-10-08
EP3954382A1 (en) 2022-02-16
JPWO2020204173A1 (es) 2020-10-08
AU2020255935A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
CR20220312A (es) Compuestos tricíclicos sustituidos
CR20220363A (es) Compuestos tricíclicos sustituidos
MY202022A (en) Pyrrolotriazine compounds as tam inhibitors
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
SG10201811384TA (en) Mnk inhibitors and methods related thereto
MX2018005019A (es) Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas.
MX2021012201A (es) Adyuvante soluble en agua.
PH12015502414A1 (en) Enhancer of zeste homolog 2 inhibitors
MX2019015744A (es) Composiciones farmaceuticas.
PH12019501690A1 (en) Pyrimidine compound and pharmaceutical use thereof
PH12021550382A1 (en) Tetrahydropyridopyrimidine derivatives as ahr modulators
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
TN2017000031A1 (en) Imidazopyridazine compounds
PH12018500852B1 (en) Novel cryptophycin compounds and conjugates, their preparation and their therapeutic use
JOP20170101B1 (ar) توليف مركبات إندازول
PH12017500737B1 (en) Kcnq2-5 channel activator
PH12019502093A1 (en) Novel ester compounds, method for the production thereof and use thereof
PH12020550703A1 (en) Sulfonamide compounds and use thereof
MX2015014688A (es) Tiazoles y usos de los mismos.
MX2019003818A (es) Metodo para la sintesis de derivado de 3-fenil-2,3,4,8,9,10-hexahi dropiran [2,3-f] cromeno e isomero optico del mismo.
MX2020006434A (es) Nuevos compuestos inhibidores del blanco mecanistico de rapamicina (mtor).
MX2019013071A (es) Metodo de tratamiento inmunoterapeutico de un tumor.
MX2021012200A (es) Adyuvante soluble en agua y composición que contiene el mismo.
MX2018004296A (es) Combinacion de un agonista selectivo de il-2rbeta y un agonista il-15 de accion prolongada.
MX2020006436A (es) Compuestos inhibidores del blanco mecanistico de rapamicina (mtor).